Recent

% | $
Quotes you view appear here for quick access.

ARCA biopharma, Inc. (ABIO) Message Board

  • joelumetta1957 joelumetta1957 Feb 1, 2013 12:27 PM Flag

    should be 300 Million dollar market cap,not 10 mill

    . The authors based their conclusions on post-hoc analyses of clinical data from a 1040 patient DNA sub study of the Phase 3 clinical trial Beta-Blocker Evaluation of Survival Trial (BEST). The BEST Trial was sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs.
    The paper shows that patients in the BEST Trial who received Gencaro experienced a 58% reduction in the incidence of ventricular tachycardia or fibrillation (“VT/VF”) (p = 0.00006), adjusted for the competing risk of mortality. In addition, the authors determined that Gencaro reduced the incidence of VT/VF by 74% (p = 0.00005) in patients with the beta-1 389 arginine homozygous genotype, believed to be present in about 50% of the U.S. population.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ABIO
0.8602-0.0199(-2.26%)Apr 17 3:59 PMEDT